The Filing Desk

Nektar Therapeutics vs Ocular Therapeutix

Nektar Therapeutics NKTR · Ocular Therapeutix OCUL · Pharmaceuticals

Nektar Therapeutics reported revenue of $55 million in fiscal 2025, about the same as Ocular Therapeutix's $52 million in fiscal 2025. Nektar Therapeutics' revenue fell 43.9% in its latest year, and Ocular Therapeutix's fell 18.5%. Nektar Therapeutics had an operating margin of -253.7%, against -519.8% at Ocular Therapeutix. Free cash flow was −$209 million at Nektar Therapeutics and −$217 million at Ocular Therapeutix.

Side by side

Nektar TherapeuticsOcular Therapeutix
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$55M$52M
Revenue growth−43.9%−18.5%
Revenue growth a year, last 5 years−18.4%24.5%
Gross margin100.0%87.3%
Operating margin−253.7%−519.8%
Net margin−297.1%−511.9%
Free cash flow−$209M−$217M
Free cash flow margin−377.8%−417.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.1%18.3%
Last close$37.27$6.21
P/E at the last close——
Insider trades, last 12 monthssold $2.4 millionbought $461,354, sold $2.8 million
Piotroski F-score2 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Nektar TherapeuticsOcular Therapeutix
Operating margin
Percent of revenue
Nektar TherapeuticsOcular Therapeutix
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nektar TherapeuticsOcular Therapeutix

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nektar Therapeutics and Ocular Therapeutix pages.